Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab with neoadjuvant chemoradiotherapy for resectable oesophageal or gastro-oesophageal junction adenocarcinoma
ACTRN12619000288123Phase 2Recruiting
- Sponsor
- Southern Adelaide Local Health Network
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma, sponsored by Southern Adelaide Local Health Network. Primary endpoints: Safety, Pathological complete response and 1 more. Started Sep 2019; status: recruiting.
02
Drugs
avelumab
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ACTRN12619000288123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000288123.